Business Description
Titan Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US8883143096
Description
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.97 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -66.47 | |||||
| Beneish M-Score | 1619.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -96.6 | |||||
| 3-Year EBITDA Growth Rate | 36.6 | |||||
| 3-Year EPS without NRI Growth Rate | 34 | |||||
| 3-Year FCF Growth Rate | 53.5 | |||||
| 3-Year Book Growth Rate | -4.9 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.03 | |||||
| 9-Day RSI | 43.08 | |||||
| 14-Day RSI | 46.36 | |||||
| 6-1 Month Momentum % | -15.02 | |||||
| 12-1 Month Momentum % | -58.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.55 | |||||
| Quick Ratio | 5.55 | |||||
| Cash Ratio | 4.68 | |||||
| Days Sales Outstanding | 9125 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.8 | |||||
| Shareholder Yield % | -2.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -727700 | |||||
| Net Margin % | -556900 | |||||
| FCF Margin % | -709200 | |||||
| ROE % | -188.24 | |||||
| ROA % | -110.83 | |||||
| ROIC % | -911.22 | |||||
| ROC (Joel Greenblatt) % | -3488.49 | |||||
| ROCE % | -244.36 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6970 | |||||
| PB Ratio | 0.82 | |||||
| Price-to-Tangible-Book | 0.82 | |||||
| EV-to-EBIT | -0.02 | |||||
| EV-to-EBITDA | -0.02 | |||||
| EV-to-Revenue | 178 | |||||
| EV-to-Forward-Revenue | 68.41 | |||||
| EV-to-FCF | -0.03 | |||||
| Price-to-Median-PS-Value | 697 | |||||
| Price-to-Net-Current-Asset-Value | 0.83 | |||||
| Price-to-Net-Cash | 1.03 | |||||
| Earnings Yield (Greenblatt) % | -5000 | |||||
| FCF Yield % | -111.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TTNP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Titan Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.001 | ||
| EPS (TTM) ($) | -7.41 | ||
| Beta | 1.44 | ||
| Volatility % | 57.44 | ||
| 14-Day RSI | 46.36 | ||
| 14-Day ATR ($) | 0.433303 | ||
| 20-Day SMA ($) | 7.134695 | ||
| 12-1 Month Momentum % | -58.46 | ||
| 52-Week Range ($) | 5 - 16.6 | ||
| Shares Outstanding (Mil) | 0.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Titan Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Titan Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Titan Pharmaceuticals Inc Frequently Asked Questions
What is Titan Pharmaceuticals Inc(TTNP)'s stock price today?
The current price of TTNP is $6.97. The 52 week high of TTNP is $16.60 and 52 week low is $5.00.
When is next earnings date of Titan Pharmaceuticals Inc(TTNP)?
The next earnings date of Titan Pharmaceuticals Inc(TTNP) is .
Does Titan Pharmaceuticals Inc(TTNP) pay dividends? If so, how much?
Titan Pharmaceuticals Inc(TTNP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers